In this review, we summarized NGF/BDNF expression and receptor activity in osteosarcoma and conducted a translational, efficacy− and safety−oriented appraisal of tissue/biofluid biomarker readouts and drugging opportunities targeting neurotrophin and co−regulatory neural circuits. This evidence concerns the gene NGF and osteosarcoma.